Export 24 results:
Author [ Title(Asc)] Type Year
Filters: Author is Mulligan, Mark J  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
V
R. Salerno-Gonçalves, Chen, W. H., Mulligan, M. J., Frey, S. E., Stapleton, J. T., Keitel, W. A., Bailey, J., Sendra, E., Hill, H., Johnson, R. A., and Sztein, M. B., “Vaccine-related major cutaneous reaction size correlates with cellular-mediated immune responses after tularaemia immunisation.”, Clin Transl Immunology, vol. 10, no. 1, p. e1239, 2021.
T
M. J. Mulligan, Stapleton, J. T., Keitel, W. A., Frey, S. E., Chen, W. H., Rouphael, N., Edupuganti, S., Beck, A., Winokur, P. L., Sahly, H. M. El, Patel, S. M., Atmar, R. L., Graham, I., Anderson, E., El-Kamary, S. S., Pasetti, M. F., Sztein, M. B., Hill, H., and Goll, J. B., “Tularemia vaccine: Safety, reactogenicity, "Take" skin reactions, and antibody responses following vaccination with a new lot of the Francisella tularensis live vaccine strain - A phase 2 randomized clinical Trial.”, Vaccine, vol. 35, no. 36, pp. 4730-4737, 2017.
J. B. Goll, Li, S., Edwards, J. L., Bosinger, S. E., Jensen, T. L., Wang, Y., Hooper, W. F., Gelber, C. E., Sanders, K. L., Anderson, E. J., Rouphael, N., Natrajan, M. S., Johnson, R. A., Sanz, P., Hoft, D., and Mulligan, M. J., “Transcriptomic and Metabolic Responses to a Live-Attenuated Vaccine.”, Vaccines (Basel), vol. 8, no. 3, 2020.
S
M. S. Natrajan, Rouphael, N., Lai, L., Kazmin, D., Jensen, T. L., Weiss, D. S., Ibegbu, C., Sztein, M. B., Hooper, W. F., Hill, H., Anderson, E. J., Johnson, R., Sanz, P., Pulendran, B., Goll, J. B., and Mulligan, M. J., “Systems Vaccinology for a Live Attenuated Tularemia Vaccine Reveals Unique Transcriptional Signatures That Predict Humoral and Cellular Immune Responses.”, Vaccines (Basel), vol. 8, no. 1, 2019.
M. J. Mulligan, Bernstein, D. I., Winokur, P., Rupp, R., Anderson, E., Rouphael, N., Dickey, M., Stapleton, J. T., Edupuganti, S., Spearman, P., Ince, D., Noah, D. L., Hill, H., and Bellamy, A. R., “Serological responses to an avian influenza A/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trial.”, JAMA, vol. 312, no. 14, pp. 1409-19, 2014.
R. B. Belshe, Frey, S. E., Graham, I., Mulligan, M. J., Edupuganti, S., Jackson, L. A., Wald, A., Poland, G., Jacobson, R., Keyserling, H. L., Spearman, P., Hill, H., and Wolff, M., “Safety and immunogenicity of influenza A H5 subunit vaccines: effect of vaccine schedule and antigenic variant.”, J Infect Dis, vol. 203, no. 5, pp. 666-73, 2011.
W. A. Keitel, Jackson, L. A., Edupuganti, S., Winokur, P. L., Mulligan, M. J., Thornburg, N. J., Patel, S. M., Rouphael, N. G., Lai, L., Bangaru, S., McNeal, M. M., Bellamy, A. R., and Hill, H. R., “Safety and Immunogenicity of a Subvirion Monovalent Unadjuvanted Inactivated Influenza A(H3N2) Variant Vaccine in Healthy Persons ≥18 Years Old.”, J Infect Dis, vol. 212, no. 4, pp. 552-61, 2015.
L. A. Jackson, Frey, S. E., Sahly, H. M. El, Mulligan, M. J., Winokur, P. L., Kotloff, K. L., Campbell, J. D., Atmar, R. L., Graham, I., Anderson, E. J., Anderson, E. L., Patel, S. M., Fields, C., Keitel, W., Rouphael, N., Hill, H., and Goll, J. B., “Safety and immunogenicity of a modified vaccinia Ankara vaccine using three immunization schedules and two modes of delivery: A randomized clinical non-inferiority trial.”, Vaccine, vol. 35, no. 13, pp. 1675-1682, 2017.
R
L. A. Jackson, Sahly, H. M. El, George, S., Winokur, P., Edwards, K., Brady, R. C., Rouphael, N., Keitel, W. A., Mulligan, M. J., Burton, R. L., Nakamura, A., Ferreria, J., and Nahm, M. H., “Randomized clinical trial of a single versus a double dose of 13-valent pneumococcal conjugate vaccine in adults 55 through 74 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.”, Vaccine, vol. 36, no. 5, pp. 606-614, 2018.
P
Y. - H. Chang, Duong, D. M., Goll, J. B., Wood, D. C., Jensen, T. L., Yin, L., Gelber, C. E., Seyfried, N. T., Anderson, E., Natrajan, M. S., Rouphael, N., Johnson, R. A., Sanz, P., Mulligan, M. J., and Hoft, D. F., “Proteomic Analysis of Human Immune Responses to Live-Attenuated Tularemia Vaccine.”, Vaccines (Basel), vol. 8, no. 3, 2020.
E. J. Anderson, Lai, L., Wrammert, J., Kabbani, S., Xu, Y., Priyamvada, L., Hill, H., Goll, J. B., Jensen, T. L., Kao, C., Yildirim, I., Rouphael, N., Jackson, L., and Mulligan, M. J., “Plasmablast, Memory B Cell, CD4+ T Cell, and Circulating Follicular Helper T Cell Responses to a Non-Replicating Modified Vaccinia Ankara Vaccine.”, Vaccines (Basel), vol. 8, no. 1, 2020.
S. E. Frey, Bernstein, D. I., Brady, R. C., Keitel, W. A., Sahly, H. El, Rouphael, N. Georges, Mulligan, M. J., Atmar, R. L., Edupuganti, S., Patel, S. M., Dickey, M., Graham, I., Anderson, E. L., Noah, D. L., Hill, H., Wolff, M., and Belshe, R. B., “Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009-2010 seasonal trivalent influenza vaccinations.”, Vaccine, vol. 33, no. 1, pp. 163-73, 2015.
N. G. Rouphael, Hurwitz, S. J., Hart, M., Beck, A., Anderson, E. J., Deye, G., Osborn, B., Cai, S. Yi, Focht, C., Amegashie, C., Bowlin, T. L., Brooks, J., and Mulligan, M. J., “Phase Ib Trial To Evaluate the Safety and Pharmacokinetics of Multiple Ascending Doses of Filociclovir (MBX-400, Cyclopropavir) in Healthy Volunteers.”, Antimicrob Agents Chemother, vol. 63, no. 9, 2019.
O
L. Lai, Rouphael, N., Xu, Y., Kabbani, S., Beck, A., Sherman, A., Anderson, E. J., Bellamy, A., Weiss, J., Cross, K., and Mulligan, M. J., “An Oil-in-Water adjuvant significantly increased influenza A/H7N9 split virus Vaccine-Induced circulating follicular helper T (cT) cells and antibody responses.”, Vaccine, vol. 40, no. 49, pp. 7065-7072, 2022.
I
R. B. Belshe, Frey, S. E., Graham, I. L., Anderson, E. L., Jackson, L. A., Spearman, P., Edupuganti, S., Mulligan, M. J., Rouphael, N., Winokur, P., Dolor, R. J., Woods, C. W., Walter, E. B., Chen, W. H., Turley, C., Edwards, K. M., C Creech, B., Hill, H., and Bellamy, A. R., “Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial.”, JAMA, vol. 312, no. 14, pp. 1420-8, 2014.
L. A. Jackson, Chen, W. H., Stapleton, J. T., Dekker, C. L., Wald, A., Brady, R. C., Edupuganti, S., Winokur, P., Mulligan, M. J., Keyserling, H. L., Kotloff, K. L., Rouphael, N., Noah, D. L., Hill, H., and Wolff, M. C., “Immunogenicity and safety of varying dosages of a monovalent 2009 H1N1 influenza vaccine given with and without AS03 adjuvant system in healthy adults and older persons.”, J Infect Dis, vol. 206, no. 6, pp. 811-20, 2012.
P. Winokur, Sahly, H. M. El, Mulligan, M. J., Frey, S. E., Rupp, R., Anderson, E. J., Edwards, K. M., Bernstein, D. I., Schmader, K., Jackson, L. A., Chen, W. H., Hill, H., and Bellamy, A., “Immunogenicity and safety of different dose schedules and antigen doses of an MF59-adjuvanted H7N9 vaccine in healthy adults aged 65 years and older.”, Vaccine, vol. S0264-410X, no. 20, pp. 31504-31508, 2021.
D
L. Lai, Ault, K., Rouphael, N., Beck, A., Domjahn, B., Xu, Y., Anderson, E. J., Cheng, A., Nakamura, A., Hoagland, R. J., Kelley, C., Edupuganti, S., Mask, K., Nesin, M., Unger, E. R., Panicker, G., David, H., and Mulligan, M. J., “Duration of Cellular and Humoral Responses after Quadrivalent Human Papillomavirus Vaccination in Healthy Female Adults with or without Prior Type 16 and/or 18 Exposure.”, Vaccines (Basel), vol. 8, no. 3, 2020.
N. Rouphael, Beck, A., Kirby, A. E., Liu, P., Natrajan, M. S., Lai, L., Phadke, V., Winston, J., Raabe, V., Collins, M. H., Girmay, T., Alvarez, A., Beydoun, N., Karmali, V., Altieri-Rivera, J., Lindesmith, L. C., Anderson, E. J., Wang, Y., El-Khorazaty, J., Petrie, C., Baric, R. S., Baqar, S., Moe, C. L., and Mulligan, M. J., “Dose-Response of a Norovirus GII.2 Controlled Human Challenge Model Inoculum”, J Infect Dis, vol. 226, no. 10, pp. 1771-1780, 2022.
C
H. M. El Sahly, Gorchakov, R., Lai, L., Natrajan, M. S., Patel, S. M., Atmar, R. L., Keitel, W. A., Hoft, D. F., Barrett, J., Bailey, J., Edupuganti, S., Raabe, V., Wu, H. M., Fairley, J., Rouphael, N., Murray, K. O., and Mulligan, M. J., “Clinical, Virologic, and Immunologic Characteristics of Zika Virus Infection in a Cohort of US Patients: Prolonged RNA Detection in Whole Blood.”, Open Forum Infect Dis, vol. 6, no. 1, p. ofy352, 2019.
L. E. Widdice, Hoagland, R., S Callahan, T., Kahn, J. A., Harrison, C. J., Pahud, B. A., Frey, S. E., Berry, A. A., Kotloff, K. L., Edwards, K. M., Mulligan, M. J., Sudman, J., Nakamura, A., and Bernstein, D. I., “Caregiver and adolescent factors associated with delayed completion of the three-dose human papillomavirus vaccination series.”, Vaccine, vol. 36, no. 11, pp. 1491-1499, 2018.
B
L. Lai, Rouphael, N., Xu, Y., Sherman, A. C., Edupuganti, S., Anderson, E. J., Lankford-Turner, P., Wang, D., Keitel, W., McNeal, M. M., Cross, K., Hill, H., Bellamy, A. R., and Mulligan, M. J., “Baseline Levels of Influenza-Specific B Cells and T Cell Responses Modulate Human Immune Responses to Swine Variant Influenza A/H3N2 Vaccine.”, Vaccines (Basel), vol. 8, no. 1, 2020.
A
L. E. Widdice, Unger, E. R., Panicker, G., Hoagland, R., S Callahan, T., Jackson, L. A., Berry, A. A., Kotloff, K., Frey, S. E., Harrison, C. J., Pahud, B. A., Edwards, K. M., Mulligan, M. J., Sudman, J., and Bernstein, D. I., “Antibody responses among adolescent females receiving two or three quadrivalent human papillomavirus vaccine doses at standard and prolonged intervals.”, Vaccine, vol. 36, no. 6, pp. 881-889, 2018.
K. M. Maner-Smith, Goll, J. B., Khadka, M., Jensen, T. L., Colucci, J. K., Gelber, C. E., Albert, C. J., Bosinger, S. E., Franke, J. D., Natrajan, M., Rouphael, N., Johnson, R. A., Sanz, P., Anderson, E. J., Hoft, D. F., Mulligan, M. J., Ford, D. A., and Ortlund, E. A., “Alterations in the Human Plasma Lipidome in Response to Tularemia Vaccination.”, Vaccines (Basel), vol. 8, no. 3, 2020.